利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

114 条记录 (耗时 0.053 秒)

    Antigen-specific clonal expansion of B cells
    3.
    发明授权
    Antigen-specific clonal expansion of B cells 有权
    B细胞的抗原特异性克隆扩增

    公开(公告)号：US08945923B2

    公开(公告)日：2015-02-03

    申请号：US13504638

    申请日：2010-10-29

    申请人： Ugur Sahin ,  Ozlem Tureci ,  Torsten Seppmann ,  Holger Hoff ,  Jens Schumacher

    发明人： Ugur Sahin ,  Ozlem Tureci ,  Torsten Seppmann ,  Holger Hoff ,  Jens Schumacher

    IPC分类号： A01N1/00 ,  C12N5/00 ,  C12N5/02 ,  C12N5/10 ,  C07K14/705

    CPC分类号： C07K14/70578 ,  C07K16/00 ,  C07K2319/30 ,  C12N5/0635

    摘要： The present invention provides recombinant proteins comprising the amino acid sequence of an intracellular segment of CD40 and an amino acid sequence mediating the association of the recombinant protein with the constant region of an immunoglobulin heavy chain. The recombinant proteins according to the present invention are useful for inducing clonal expansion of a B cell having a predetermined antigen-specificity without the need for T cell or CD40L mediated co-stimulation. Thus, the present invention provides tools for clonal expansion of B cells specific for an antigen of interest and the production of B cells secreting antibodies specific for an antigen of interest. The recombinant proteins of the present invention may also be used for generating fully human monoclonal antibodies with a predetermined antigen-specificity from the B cell repertoire of a human subject.

    摘要翻译： 本发明提供重组蛋白，其包含CD40的细胞内节段的氨基酸序列和介导重组蛋白与免疫球蛋白重链的恒定区的缔合的氨基酸序列。 根据本发明的重组蛋白质可用于诱导具有预定抗原特异性的B细胞的克隆扩增，而不需要T细胞或CD40L介导的共刺激。 因此，本发明提供了用于针对感兴趣的抗原特异性的B细胞的克隆扩增的工具，以及产生分泌针对感兴趣的抗原的抗体的B细胞。 本发明的重组蛋白还可用于从人受试者的B细胞库中产生具有预定抗原特异性的完全人单克隆抗体。

    MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER
    6.
    发明申请
    MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER 有权
    用于治疗癌症的单克隆抗体

    公开(公告)号：US20130071325A1

    公开(公告)日：2013-03-21

    申请号：US13636277

    申请日：2011-03-10

    申请人： Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Rita Mitnacht-Kraus

    发明人： Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Rita Mitnacht-Kraus

    IPC分类号： C07K16/30

    CPC分类号： C07K16/30 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/462 ,  C07K16/464 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/76 ,  C12N5/163 ,  C12N15/1138 ,  C12N2310/14

    摘要： The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.

    摘要翻译： 本发明提供了可用作治疗和/或预防与表达GT468的细胞相关的疾病的治疗剂的抗体，包括肿瘤相关疾病如乳腺癌，肺癌，胃癌，卵巢癌，肝细胞癌，结肠癌，胰腺癌，食管癌 癌症，头颈癌，肾癌，特别是肾细胞癌，前列腺癌，肝癌，黑素瘤，肉瘤，骨髓瘤，成神经细胞瘤，胎盘绒毛膜癌，子宫颈癌和甲状腺癌及其转移形式。 在一个实施方案中，肿瘤疾病是肺中的转移性癌症。

    Autoantigenes for improved diagnosis, prognosis and treatment of inflammatory neurological diseases
    7.
    发明授权
    Autoantigenes for improved diagnosis, prognosis and treatment of inflammatory neurological diseases 失效
    用于改善炎症性神经疾病的诊断，预后和治疗的自身抗原

    公开(公告)号：US08399210B2

    公开(公告)日：2013-03-19

    申请号：US12420627

    申请日：2009-04-08

    申请人： Ugur Sahin ,  Özlem Türeci ,  Alexander Zaigler

    发明人： Ugur Sahin ,  Özlem Türeci ,  Alexander Zaigler

    IPC分类号： G01N33/53 ,  G01N33/537 ,  G01N33/567

    CPC分类号： G01N33/564 ,  G01N33/56972 ,  G01N2800/285

    摘要： According to the invention, autoantibodies, the appearance of which is characteristic of neurological autoimmune diseases, especially multiple sclerosis, are detected and the respective autoantigens identified. It can further be shown that many of these autoantigens are expressed specifically in the brain. The identification of the autoantigens and autoantibodies is useful for diagnosis and treatment. A brain-specific expression of the autoantigens further emphasizes an important role of the antigens and antibodies in the origin and development of neurological autoimmune diseases.

    摘要翻译： 根据本发明，检测其外观是神经性自身免疫性疾病，特别是多发性硬化症的特征的自身抗体，并鉴定出相应的自身抗原。 可以进一步表明，许多这些自身抗原在脑中特异性表达。 自身抗体和自身抗体的鉴定对于诊断和治疗是有用的。 自身抗原的脑特异性表达进一步强调了抗原和抗体在神经性自身免疫性疾病的起源和发展中的重要作用。

    Compositions and methods for therapy and diagnosis of cancer
    10.
    发明授权
    Compositions and methods for therapy and diagnosis of cancer 失效
    癌症治疗和诊断的组成和方法

    公开(公告)号：US08088913B2

    公开(公告)日：2012-01-03

    申请号：US12096216

    申请日：2006-12-07

    申请人： Ugur Sahin ,  Özlem Türeci ,  Michael Koslowski

    发明人： Ugur Sahin ,  Özlem Türeci ,  Michael Koslowski

    IPC分类号： C07H21/04 ,  C07H21/02 ,  C12N15/63 ,  A61K48/00

    CPC分类号： C12N15/1138 ,  C07K14/4748 ,  C12N15/1137 ,  C12N2310/14 ,  C12Y301/03048

    摘要： The present invention is directed to siRNA molecules which specifically target and cause RNAi-induced degradation of mRNA from TPTE genes, so that the protein product of the TPTE gene is not produced or is produced in reduced amounts. The siRNA compounds and compositions of the invention are useful for treating diseases which require inhibition of TPTE expression for their treatment, in particular cancer pathologies. The present invention also includes methods which make possible to assess and/or prognose the metastatic behavior of a cancer disease and/or the occurrence of a relapse of cancer.

    摘要翻译： 本发明涉及特异性靶向并引起来自TPTE基因的mRNA的RNAi诱导的降解的siRNA分子，使得TPTE基因的蛋白质产物不产生或以减少的量产生。 本发明的siRNA化合物和组合物可用于治疗需要抑制TPTE表达以治疗，特别是癌症病症的疾病。 本发明还包括使得有可能评估和/或预测癌症疾病的转移行为和/或癌症复发的方法。